EU issues first-ever pharmaceutical cartel decision
Boehringer Ingelheim and five other drugmakers have agreed to pay the European Commission €13.4 million in a hybrid settlement decision after admitting to participating in a global cartel to fix the price of an essential stomach medicine.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.